IHM
ITCI

Iguana Healthcare Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Iguana Healthcare Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25,000
Closed -$971K – 102
2016
Q2 		$971K Sell
25,000
-25,000
-50% -$898K 0.4% 66
2016
Q1 		$1.39M Buy
+50,000
New +$1.67M 0.51% 52

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Iguana Healthcare Management's ITCI Position: Q3 2016 in Review

Iguana Healthcare Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 25,000 shares — an estimated $971K sold.

Iguana Healthcare Management first reported a position in ITCI in Q1 2016 and held it in 2 quarters. The position peaked at $1.39M in Q1 2016. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • Iguana Healthcare Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
  • Iguana Healthcare Management sold 25,000 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $971K.
  • Iguana Healthcare Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 2 quarters.
  • Iguana Healthcare Management's Intra-Cellular Therapies Inc. position peaked at $1.39M in Q1 2016.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Iguana Healthcare Management's 13F filing for Q3 2016, filed 14 Nov 2016.